Karyopharm Therapeutics Corporate Update November 2016

Karyopharm Therapeutics presents a corporate update on its pipeline of SINE™ compounds, including lead candidate selinexor (KPT-330) for cancer treatment. The presentation outlines clinical development progress, regulatory catalysts expected over 18 months, and the company's strong cash position through end of 2018. Karyopharm is led by experienced oncology executives with a track record in accelerated drug approvals and commercialization.